Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
about
Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations.Primer on tumor immunology and cancer immunotherapyDiscrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-lifeAntibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2.Trends in cancer immunotherapyLUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.Real-time PCR analysis of genes encoding tumor antigens in esophageal tumors and a cancer vaccine.NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen.Quantification of SSX mRNA expression in human bone and soft tissue tumors using nucleic acid sequence-based amplification.Human melanoma-specific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo.Immunotherapeutic strategies for high-risk bladder cancer.Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospectsGeneration of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design.Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residuesToward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccinesAn immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation.Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen.TFDP3 Regulates Epithelial-Mesenchymal Transition in Breast Cancer.T-cell receptor-engineered T cells for cancer treatment: current status and future directions.Immune targets and neoantigens for cancer immunotherapy and precision medicine.Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populationsMultiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.In silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes.Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma.SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade.Testing for HLA/peptide tetramer-binding to the T cell receptor complex on human T lymphocytes.
P2860
Q24533572-830D4C73-A0D0-4DA2-A40A-67D10C50ED63Q27001126-F7AAFF66-D786-426B-990F-E93312F7CC17Q33943148-61E0D55D-D61D-4ABE-89CF-E709BE4586B0Q33957896-5CC4C40B-0C36-49BB-B701-CC71BB83696DQ33987977-AA68CF9E-D6DB-4201-A02D-AC0B212BAB37Q33994533-DBD0F254-06B0-465E-B96A-F26552719828Q34052702-E2F9B309-8392-4572-A2FA-493C125E1642Q34111719-A201674A-DF85-472B-99A5-7E32CB195899Q34111803-4A47BF5A-BDC6-4C31-A5AE-EC8D0F8A4272Q34325790-E05E8F70-C72E-428E-BDAE-191B37ADDEC7Q34388367-93ECBE59-E169-4C26-9AA7-96FBB20E1896Q34606735-32C8032C-07D9-41E4-8070-441D426E2F3BQ34691545-5579E212-B22C-491A-80C5-6CC7027E7892Q34721861-3F0F6FB3-455D-4677-8C4D-9173AB06AF18Q35789880-00658CE2-1B92-419C-AB4D-8BC437771A40Q36057468-07B0A05B-BF9D-4705-9169-A07CD4EDB878Q36768976-75B706E1-51B6-4EC9-A9F0-ECE1EC7CF4B3Q36778827-B56244A8-7AEA-4343-813F-3DD79B1F2750Q36924658-75A5BD31-8F8A-40BC-B864-FE81E317240BQ36937141-2AEC7CF1-3608-4E13-93A7-5576E9AF1FA9Q36973865-187635E8-0285-4BBF-9889-E98CD4F4ACFEQ37137360-863D11C1-4A97-4188-829C-01F1276C61EFQ37370515-20B4A72B-6E4A-46CF-AFC8-BB70ED3AD2BCQ37513109-F26E0A48-22F0-4D9A-B239-5BF9B78426C9Q37569023-0F909047-76D9-4859-B5AA-7C98DA8E35B6Q37570169-EC2F20D9-4A7E-4340-94B3-3AF8453E8723Q37600542-15245606-7471-44D7-8541-3B696E1A8373Q38767662-4299831C-9557-4CB4-89C0-9DF165D790D6Q39057617-FDC1EAC5-E804-4B66-A747-54B19E3F371DQ39506462-1C2175D6-1067-4FEC-9B52-E048BACCDDA3Q39740168-5BB572F9-5BF8-4E95-B40E-61761F15C16AQ40188864-6C110ED5-8BB2-4FAC-B54F-31ABDDD4CC24Q40259357-4D82970D-3FCD-430A-9182-0E8A7851D193Q41894814-E83EFB70-C6C1-4344-A622-2529F792BD19Q42796696-E15F1B34-F047-470B-8C26-7B3777F86C33
P2860
Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Naturally occurring human lymp ...... NY-ESO-1 in melanoma patients.
@ast
Naturally occurring human lymp ...... NY-ESO-1 in melanoma patients.
@en
type
label
Naturally occurring human lymp ...... NY-ESO-1 in melanoma patients.
@ast
Naturally occurring human lymp ...... NY-ESO-1 in melanoma patients.
@en
prefLabel
Naturally occurring human lymp ...... NY-ESO-1 in melanoma patients.
@ast
Naturally occurring human lymp ...... NY-ESO-1 in melanoma patients.
@en
P2093
P1433
P1476
Naturally occurring human lymp ...... NY-ESO-1 in melanoma patients
@en
P2093
Cerottini JC
Champagne P
Ellefsen K
P304
P407
P50
P577
2000-08-01T00:00:00Z